{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:38:26Z","timestamp":1790854706775,"version":"4.1.0"},"reference-count":47,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Background: Diabetic peripheral neuropathy (DPN) affects up to 50% of diabetes patients and is driven by hyperglycemia-induced oxidative stress, mitochondrial dysfunction, polyol pathway activation, advanced glycation end-product formation, and inflammation. Current management is largely symptomatic, prompting interest in metabolic\/nutritional therapies. This review critically evaluates the mechanistic rationale and clinical evidence for alpha-lipoic acid (ALA) and benfotiamine as adjunctive treatments for DPN. Methods: A structured narrative review of PubMed\/MEDLINE was conducted using predefined keywords for DPN, oxidative stress, metabolic therapy, and thiamine derivatives. Randomized controlled trials, clinical studies, systematic reviews, and relevant experimental studies were included. Evidence was synthesized qualitatively with emphasis on mechanistic plausibility, clinical efficacy, intervention duration, and methodological rigor. Results: ALA consistently improves short-term symptoms across multiple randomized trials. The long-term NATHAN 1 trial reported a marginal, borderline significant effect on the primary composite endpoint (NIS-LL, p = 0.05) without significant improvements in nerve conduction studies; therefore, evidence for functional stabilization is very limited and inconclusive. ALA\u2019s effects are attributed to antioxidant activity, mitochondrial protection, and improved microvascular function. Benfotiamine has a strong biochemical rationale (transketolase activation, diversion of glycolytic intermediates from damaging pathways), but clinical evidence remains limited to short-duration, symptom-based studies, with no large-scale, long-term trials published. Conclusions: Both agents target key pathways in DPN pathogenesis. ALA is the most established adjunctive metabolic therapy for symptomatic DPN, although no study has demonstrated structural nerve regeneration or a definitive disease-modifying effect. Benfotiamine is biologically plausible but requires further validation in long-term randomized trials with structural and biomarker-based endpoints. Outside of documented thiamine deficiency, its routine use cannot be recommended based on current evidence.<\/jats:p>","DOI":"10.3390\/nu18101538","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:04:36Z","timestamp":1778601876000},"page":"1538","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Alpha-Lipoic Acid and Benfotiamine in Diabetic Peripheral Neuropathy: A Critical Review of Mechanistic Rationale and Clinical Evidence Within a Nutritional Therapeutic Framework"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2079-2383","authenticated-orcid":false,"given":"Alin","family":"Ciubotaru","sequence":"first","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Grosu","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Alexa","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1544-1325","authenticated-orcid":false,"given":"Laura-Elena","family":"Cucu","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4495-4004","authenticated-orcid":false,"given":"Thomas Gabriel","family":"Schreiner","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u0103t\u0103lina Elena","family":"Bistriceanu","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0008-9696","authenticated-orcid":false,"given":"Alexandra","family":"Ma\u015ftaleru","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doina","family":"Azoic\u0101i","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Vamanu","sequence":"additional","affiliation":[{"name":"Basic and Clinical Neuroscience Department, Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, London SE5 8AF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandru","family":"Patrascu","sequence":"additional","affiliation":[{"name":"Apollonia University, 700511 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan Iulian","family":"Cuciureanu","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6952-9741","authenticated-orcid":false,"given":"Emilian Bogdan","family":"Ignat","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41572-019-0092-1","article-title":"Diabetic neuropathy","volume":"5","author":"Feldman","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2337\/dc16-2042","article-title":"Diabetic neuropathy: A position statement by the American Diabetes Association","volume":"40","author":"Boulton","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/414813a","article-title":"Biochemistry and molecular cell biology of diabetic complications","volume":"414","author":"Brownlee","year":"2001","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/BF00400603","article-title":"Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant alpha-lipoic acid: A 3-week multicentre randomized controlled trial (ALADIN Study)","volume":"38","author":"Ziegler","year":"1995","journal-title":"Diabetologia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.2337\/diacare.22.8.1296","article-title":"Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: A 7-month multicenter randomized controlled trial (ALADIN III Study)","volume":"22","author":"Ziegler","year":"1999","journal-title":"Diabetes Care"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"770","DOI":"10.2337\/diacare.26.3.770","article-title":"The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: The SYDNEY trial","volume":"26","author":"Ametov","year":"2003","journal-title":"Diabetes Care"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.2337\/dc06-1216","article-title":"Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: The SYDNEY 2 trial","volume":"29","author":"Ziegler","year":"2006","journal-title":"Diabetes Care"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.phrs.2010.02.008","article-title":"The multifaceted therapeutic potential of benfotiamine","volume":"61","author":"Balakumar","year":"2010","journal-title":"Pharmacol. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/nm834","article-title":"Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy","volume":"9","author":"Hammes","year":"2003","journal-title":"Nat. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00592-008-0042-y","article-title":"Effects of thiamine and benfotiamine on intracellular glucose metabolism and relevance in the prevention of diabetic complications","volume":"45","author":"Beltramo","year":"2008","journal-title":"Acta Diabetol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1055\/s-0029-1211460","article-title":"A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy","volume":"104","author":"Stracke","year":"1996","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1055\/s-2008-1065351","article-title":"Benfotiamine in diabetic polyneuropathy (BENDIP): Results of a randomized, double-blind, placebo-controlled clinical study","volume":"116","author":"Stracke","year":"2008","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s001250051591","article-title":"Advanced glycation end-products: A review","volume":"44","author":"Singh","year":"2001","journal-title":"Diabetologia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1474-4422(12)70065-0","article-title":"Diabetic neuropathy: Clinical manifestations and current treatments","volume":"11","author":"Callaghan","year":"2012","journal-title":"Lancet Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1056\/NEJMra1615439","article-title":"Diabetic foot ulcers and their recurrence","volume":"376","author":"Armstrong","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_16","unstructured":"DCCT\/EDIC Research Group (2021). Effect of intensive diabetes therapy on the progression of diabetic peripheral neuropathy in the DCCT\/EDIC. Diabetes, 70, 1046\u20131055."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/CIRCRESAHA.110.223545","article-title":"Oxidative stress and diabetic complications","volume":"107","author":"Giacco","year":"2010","journal-title":"Circ. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2174\/138945008783431781","article-title":"Aldose reductase, still a compelling target for diabetic neuropathy","volume":"9","author":"Oates","year":"2008","journal-title":"Curr. Drug Targets"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1161\/CIRCRESAHA.110.217117","article-title":"Activation of protein kinase C isoforms and its impact on diabetic complications","volume":"106","author":"Geraldes","year":"2010","journal-title":"Circ. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1210\/er.2003-0019","article-title":"Oxidative stress in the pathogenesis of diabetic neuropathy","volume":"25","author":"Vincent","year":"2004","journal-title":"Endocr. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.neuron.2017.02.005","article-title":"New horizons in diabetic neuropathy: Mechanisms, bioenergetics, and pain","volume":"93","author":"Feldman","year":"2017","journal-title":"Neuron"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/jbt.10058","article-title":"Diabetes, oxidative stress, and antioxidants: A review","volume":"17","author":"Maritim","year":"2003","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.2337\/diabetes.50.12.2792","article-title":"Diabetes-associated sustained activation of the transcription factor nuclear factor-\u03baB","volume":"50","author":"Bierhaus","year":"2001","journal-title":"Diabetes"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000052077","article-title":"Neurotrophic factors and diabetic peripheral neuropathy","volume":"41","author":"Apfel","year":"1999","journal-title":"Eur. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.2337\/diab.46.2.S43","article-title":"Role of neurotrophins in diabetic neuropathy and treatment with nerve growth factors","volume":"46","author":"Tomlinson","year":"1997","journal-title":"Diabetes"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"38329","DOI":"10.1074\/jbc.R100026200","article-title":"A trail of research from lipoic acid to alpha-keto acid dehydrogenase complexes","volume":"276","author":"Reed","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/10715769409147509","article-title":"Lipoic and dihydrolipoic acids as antioxidants","volume":"20","author":"Scott","year":"1994","journal-title":"Free Radic. Res."},{"key":"ref_28","first-page":"829","article-title":"Influence of alpha-lipoic acid on intracellular glutathione in vitro and in vivo","volume":"42","author":"Busse","year":"1992","journal-title":"Arzneimittelforschung"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0006-2952(95)00116-H","article-title":"Thioctic acid: A therapeutic metal-chelating antioxidant?","volume":"50","author":"Ou","year":"1995","journal-title":"Biochem. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/0006-291X(92)90275-P","article-title":"Alpha-lipoic acid is a potent inhibitor of NF-kappa B activation in human T cells","volume":"189","author":"Suzuki","year":"1992","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1055\/s-2000-7739","article-title":"Effects of alpha-lipoic acid on microcirculation in patients with peripheral diabetic neuropathy","volume":"108","author":"Haak","year":"2000","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_32","first-page":"742","article-title":"Pathogenesis and molecular treatment strategies of diabetic neuropathy","volume":"12","author":"Mizukami","year":"2021","journal-title":"J. Diabetes Investig."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.2337\/dc11-0503","article-title":"Efficacy and safety of antioxidant treatment with alpha-lipoic acid over 4 years in diabetic polyneuropathy: The NATHAN 1 trial","volume":"34","author":"Ziegler","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_34","first-page":"334","article-title":"Alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: A meta-analysis","volume":"29","author":"Mijnhout","year":"2012","journal-title":"Diabet. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1900\/RDS.2009.6.230","article-title":"Alpha-lipoic acid and diabetic neuropathy","volume":"6","author":"Vallianou","year":"2009","journal-title":"Rev. Diabet. Stud."},{"key":"ref_36","first-page":"47","article-title":"Pharmacokinetics of thiamine derivatives especially of benfotiamine","volume":"34","author":"Loew","year":"1996","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.2337\/dc06-0531","article-title":"Benfotiamine prevents macro- and microvascular endothelial dysfunction following a meal rich in advanced glycation end products in individuals with type 2 diabetes","volume":"29","author":"Stirban","year":"2006","journal-title":"Diabetes Care"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1055\/s-2001-17399","article-title":"Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats","volume":"109","author":"Stracke","year":"2001","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.2337\/diabetes.52.8.2110","article-title":"Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine","volume":"52","author":"Karachalias","year":"2003","journal-title":"Diabetes"},{"key":"ref_40","first-page":"220","article-title":"Effectiveness of different benfotiamine dosage regimens in painful diabetic neuropathy","volume":"49","author":"Winkler","year":"1999","journal-title":"Arzneimittelforschung"},{"key":"ref_41","first-page":"CD004573","article-title":"Vitamin B for treating peripheral neuropathy","volume":"3","author":"Ang","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/dme.13798","article-title":"Reduced vitamin D levels in painful diabetic peripheral neuropathy","volume":"36","author":"Shillo","year":"2019","journal-title":"Diabet. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e3361","DOI":"10.1002\/dmrr.3361","article-title":"Vitamin D deficiency is associated with painful diabetic neuropathy","volume":"37","author":"Alam","year":"2021","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1517\/13543776.2014.937425","article-title":"Therapeutic applications of lipoic acid: A patent review (2011\u20132014)","volume":"24","author":"Koufaki","year":"2014","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1570-0232(02)00010-7","article-title":"High-performance liquid chromatographic assay for alpha-lipoic acid and five of its metabolites in human plasma and urine","volume":"769","author":"Teichert","year":"2002","journal-title":"J. Chromatogr. B"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Hsieh, R.-Y., Huang, I.-C., Chen, C., and Sung, J.-Y. (2023). Effects of Oral Alpha-Lipoic Acid Treatment on Diabetic Polyneuropathy: A Meta-Analysis and Systematic Review. Nutrients, 15.","DOI":"10.3390\/nu15163634"},{"key":"ref_47","first-page":"CD012967","article-title":"Alpha-lipoic acid for diabetic peripheral neuropathy","volume":"1","author":"Baicus","year":"2024","journal-title":"Cochrane Database Syst. Rev."}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/18\/10\/1538\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:17:05Z","timestamp":1779250625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/18\/10\/1538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":47,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["nu18101538"],"URL":"https:\/\/doi.org\/10.3390\/nu18101538","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]}}}